Stay updated on Dapagliflozin Impact on Peak VO2 in HFrEF Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on Peak VO2 in HFrEF Clinical Trial page.

Latest updates to the Dapagliflozin Impact on Peak VO2 in HFrEF Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedAdded a new Revision: v3.3.3 and removed the HHS Vulnerability Disclosure and Revision: v3.3.2 from the page footer. These changes are cosmetic and do not alter study data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe Record History shows a new revision entry v3.3.2 added and the prior revision v3.3.1 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check36 days agoChange DetectedThe record history shows a new revision entry (v3.3.1) and the prior revision (v3.2.0) in the history, reflecting minor site version updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check43 days agoChange DetectedRemoval of the government funding operating status notice from the page footer.SummaryDifference0.7%

- Check57 days agoChange DetectedThe history shows multiple version updates to core trial information, including Study Status, Recruitment Status, and the Arms/Interventions sections. These updates indicate changes to the trial's current state and design over time.SummaryDifference0.1%

- Check86 days agoChange DetectedDifference12%

Stay in the know with updates to Dapagliflozin Impact on Peak VO2 in HFrEF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on Peak VO2 in HFrEF Clinical Trial page.